For some time, patients with schizophrenia or major depressive disorder have received treatment through antipsychotic drugs. Those drugs come with a risk of side effects.
Atypical antipsychotics (AAPs) are frequently used for treatment for schizophrenia or major depressive disorder. Although they generally work better than older antipsychotics in treating key symptoms, they still run the risk of side effects. The study Assessing the Burden of Treatment-Emergent Adverse Events Associated with Atypical Medications, published in BMC Psychiatry, qualitatively assessed the occurrence and burden of side effects from these drugs from both patients’ and physician’s perspectives.
Data in this study was gathered based on physician- and patient-reported observations. Study results suggest that physicians should consider side effect profiles and individualize medication selection based on what is most important to the patient.
RTI Health Solutions researchers and PhD-level psychologists T. Michelle Brown and Dana DiBenedetti designed and implemented the study upon which this manuscript is based. Dr. Brown has been published in the Journal of Attention Disorders, Journal of Managed Care Pharmacy, Gynecologic Oncology, Haemophilia, and the Journal of Occupational and Environmental Medicine. Dr. DiBenedetti has authored numerous manuscripts and scientific presentations on instrument development and quality of life, and has served as a reviewer for several journals, including Value in Health, Clinical Therapeutics, Journal of Consulting and Clinical Psychology, Health Psychology, Annals of Behavioral Medicine, International Journal of Behavioral Medicine, Addictive Behaviors, and Medical Care.
Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications. Llorca PM, Lancon C, Hartry A, Brown TM, DiBenedetti DB, Kamat SA, Francois C.